HbA1c Response to Open-Label (OL) Empagliflozin (EMPA) with Metformin (MET) in Patients with Type 2 Diabetes (T2DM)

被引：0
|
作者：
Schernthaner, Guntram
Tinahones, Francisco J.
Goetz, Sophia
Lee, Christopher
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1288-P
引用
收藏
页码：A345 / A346
页数：2
相关论文
共 50 条
  • [31] Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data
    Lund, S.
    Solimando, F.
    Kohler, S.
    Zeller, C.
    Kaspers, S.
    DIABETOLOGIA, 2016, 59 : S26 - S27
  • [32] Effect of LSG on HbA1c Levels in T2DM Patients at One Year
    不详
    OBESITY SURGERY, 2009, 19 (08) : 1005 - 1006
  • [33] Effect of Iron Deficiency Anaemia on HbA1c levels in a cohort of patients with Type 2 diabetes mellitus (T2DM) in Sri Lanka
    Kariyawasan, Chitranga
    Dissanayaka, Champika
    Balasuriya, Thushara
    Ranatunga, Charith
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 184 - 185
  • [34] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    DIABETES, 2013, 62 : A282 - A282
  • [35] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Kovacs, Christopher
    Seshiah, Veeraswamy
    Swallow, Ros
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A291 - A291
  • [36] Ramate as add-on to metformin (MET) in obese subjects with type 2 diabetes (T2DM)
    Toplak, H
    Vercruysse, F
    Sun, X
    Fitchet, M
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S159 - S159
  • [37] EXENATIDE ONCE-WEEKLY (EQW) PHARMACOKINETICS AND HBA1C EXPOSURE RESPONSE ARE SIMILAR BETWEEN ADOLESCENT PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AND ADULTS WITH T2DM.
    Edlund, H.
    Melin, J.
    Penland, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S40 - S40
  • [38] Safety and Tolerability of Combinations of Empagliflozin/Linagliptin (EMPA/LINA) for 52 Weeks in Subjects with Type 2 Diabetes (T2DM)
    Patel, Sanjay
    Defronzo, Ralph A.
    Lewin, Andrew
    Liu, Dacheng
    Kaste, Renee
    Kohler, Sven
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A326 - A327
  • [39] Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension
    Tikkanen, I.
    Narko, K.
    Zeller, C.
    Green, A.
    Salsali, A.
    Broedl, U. C.
    Woerle, H. J.
    DIABETOLOGIA, 2013, 56 : S377 - S377
  • [40] Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Renal Impairment (RI)
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A286 - A286
12345